CR or PR – Active Featured

January 18, 20200

In Relapsed Chronic Lymphocytic Leukemia Ofatumumab May Extend Linger

Ofatumumab support treatment seems to delay movement free endurance (PFS) in patients with backslid constant lymphocytic leukemia (CLL), as indicated